IBKS No3 SPAC (225430) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IBKS No3 SPAC (225430) has a cash flow conversion efficiency ratio of -0.064x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.77 Billion ≈ $-1.20 Million USD) by net assets (₩27.43 Billion ≈ $18.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 225430 equity financing ratio to measure how much of total assets are equity-financed.
IBKS No3 SPAC - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how IBKS No3 SPAC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is IBKS No3 SPAC's earnings quality to evaluate the quality of earnings relative to operating cash generation.
IBKS No3 SPAC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IBKS No3 SPAC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Truscott Mining Corporation Ltd
AU:TRM
|
-0.049x |
|
CSP Steel Center Public Company Limited
BK:CSP
|
0.055x |
|
Realfiction Holding AB
ST:REALFI
|
-0.154x |
|
Data Storage Corp
NASDAQ:DTST
|
-0.167x |
|
Castelbajac Co. Ltd
KQ:308100
|
0.011x |
|
DGB Group NV
AS:DGB
|
0.235x |
|
Heart Test Laboratories Inc. Common Stock
NASDAQ:HSCS
|
-558.107x |
|
Delta Manufacturing Limited
NSE:DELTAMAGNT
|
-0.091x |
Annual Cash Flow Conversion Efficiency for IBKS No3 SPAC (2016–2025)
The table below shows the annual cash flow conversion efficiency of IBKS No3 SPAC from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of IBKS No3 SPAC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩28.27 Billion ≈ $19.16 Million |
₩-1.75 Billion ≈ $-1.19 Million |
-0.062x | +0.76% |
| 2024-12-31 | ₩32.62 Billion ≈ $22.10 Million |
₩-2.04 Billion ≈ $-1.38 Million |
-0.062x | -253.12% |
| 2023-12-31 | ₩35.48 Billion ≈ $24.04 Million |
₩1.45 Billion ≈ $980.06K |
0.041x | +1686.79% |
| 2022-12-31 | ₩36.33 Billion ≈ $24.62 Million |
₩-93.32 Million ≈ $-63.24K |
-0.003x | -104.52% |
| 2021-12-31 | ₩39.91 Billion ≈ $27.04 Million |
₩2.27 Billion ≈ $1.54 Million |
0.057x | +154.79% |
| 2020-12-31 | ₩40.77 Billion ≈ $27.63 Million |
₩909.18 Million ≈ $616.14K |
0.022x | +176.93% |
| 2019-12-31 | ₩24.19 Billion ≈ $16.40 Million |
₩-701.24 Million ≈ $-475.22K |
-0.029x | -156.77% |
| 2018-12-31 | ₩23.83 Billion ≈ $16.15 Million |
₩1.22 Billion ≈ $824.56K |
0.051x | +1058.34% |
| 2017-12-31 | ₩8.48 Billion ≈ $5.74 Million |
₩-45.15 Million ≈ $-30.60K |
-0.005x | +35.53% |
| 2016-12-31 | ₩8.46 Billion ≈ $5.73 Million |
₩-69.90 Million ≈ $-47.37K |
-0.008x | -- |
About IBKS No3 SPAC
KMPHARMACEUTICAL Co.,Ltd. engages in the manufacture, wholesale, and retail of oral care, beauty care, and other daily necessities in South Korea and internationally. The company offers toothpastes, toothbrushes, cosmetics, masks, hand cream, toothbrush and toothpaste, kids toothbrush, and baby finger toothbrush sets. It also provides children's safety gargles, baby and light wipes, wet wipes, an… Read more